

ASX Release

Appendix 3Y – Change in Director’s Interests Notice

29 June 2016, Sydney, Australia: Viralytics Limited (ASX: VLA) (**Viralytics**) yesterday issued 2,500,000 fully paid ordinary shares on the exercise of options with an exercise price of \$0.70.

600,000 of the options were exercised by the Company’s Chairman, Mr Paul Hopper. Mr Hopper has sold 510,000 of those shares, the proceeds of which were used to finance the exercise of the options and cover tax liabilities arising from the transactions.

As a result of the exercise of the options and sale of shares, Mr Hopper’s total holding (including shares held by his spouse) has increased by 90,000 to 160,106 VLA shares.

Details of Mr Hopper’s trades are detailed in the attached Appendix 3Y.

About VIRALYTICS and CAVATAK™

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company’s lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. Intratumoral, intravenous and intravesicular delivery routes are under investigation. Two combination studies with checkpoint inhibitors are underway in advanced melanoma patients, as well as a combination study of CAVATAK and KEYTRUDA in late-stage lung and bladder cancer patients.

Further details on our clinical and pre-clinical data can be found at: <http://www.viralytics.com/our-pipeline/clinical-trials/>

CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific ‘receptor’ proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics’ ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Viralytics Contact:

Mr Paul Hopper
Chairman
Tel 02 9988 4000

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	VIRALYTICS LIMITED
ABN	12 010 657 351

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Paul Hopper
Date of last notice	9 May 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Kilinwata Investments Pty Ltd ACN 009 641 212 – of which Mr Hopper is a shareholder
Date of change	1) 28 June 2016 2) 28 June 2016
No. of securities held prior to change	70,106 ordinary fully paid shares <ul style="list-style-type: none">36,000 ordinary fully paid shares held by Ms Deborah Coleman - Mr Hopper's spouse.34,106 ordinary fully paid shares held by Kilinwata Investments Pty Ltd 1,100,000 unquoted options held by Kilinwata Investments Pty Ltd
Class	1) Unquoted options and fully paid ordinary shares 2) Fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	1) 600,000 fully paid ordinary shares upon exercise of unquoted options 2) Nil
Number disposed	1) 600,000 unquoted options exercised 2) 510,000 fully paid ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1) Exercise price of \$0.70 per share 2) \$0.87 per share
No. of securities held after change	160,106 ordinary fully paid shares <ul style="list-style-type: none"> 36,000 ordinary fully paid shares held by Ms Deborah Coleman - Mr Hopper's spouse. 124,106 ordinary fully paid shares held by Kilinwata Investments Pty Ltd 500,000 unquoted options held by Kilinwata Investments Pty Ltd
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Exercise of unquoted options and issue of shares. 2) Off-market sale, the proceeds of which were used to finance the exercise of the options and cover tax liabilities arising from the transactions.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.